Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475-03B study of post-checkpoint inhibitor treatments for advanced clear cell renal cell carcinoma
NL-OMON59310Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mk-4830, pembrolizumab, quavonlimab, favezelimab, lenvatinib and 1 more in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with one or more dose-limiting toxicities, Number of participants with one or more adverse events and 5 more. Started Jun 2023; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON59310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59310.